Literature DB >> 26956253

Mosaic CREBBP mutation causes overlapping clinical features of Rubinstein-Taybi and Filippi syndromes.

Tamar I de Vries1, Glen R Monroe1, Martine J van Belzen2, Christian A van der Lans2, Sanne Mc Savelberg1, William G Newman3, Gijs van Haaften1, Rutger A Nievelstein4, Mieke M van Haelst1.   

Abstract

Rubinstein-Taybi syndrome (RTS, OMIM 180849) and Filippi syndrome (FLPIS, OMIM 272440) are both rare syndromes, with multiple congenital anomalies and intellectual deficit (MCA/ID). We present a patient with intellectual deficit, short stature, bilateral syndactyly of hands and feet, broad thumbs, ocular abnormalities, and dysmorphic facial features. These clinical features suggest both RTS and FLPIS. Initial DNA analysis of DNA isolated from blood did not identify variants to confirm either of these syndrome diagnoses. Whole-exome sequencing identified a homozygous variant in C9orf173, which was novel at the time of analysis. Further Sanger sequencing analysis of FLPIS cases tested negative for CKAP2L variants did not, however, reveal any further variants. Subsequent analysis using DNA isolated from buccal mucosa revealed a mosaic variant in CREBBP. This report highlights the importance of excluding mosaic variants in patients with a strong but atypical clinical presentation of a MCA/ID syndrome if no disease-causing variants can be detected in DNA isolated from blood samples. As the striking syndactyly observed in the present case is typical for FLPIS, we suggest CREBBP analysis in saliva samples for FLPIS syndrome cases in which no causal CKAP2L variant is detected.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26956253      PMCID: PMC4989203          DOI: 10.1038/ejhg.2016.14

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  21 in total

1.  Filippi syndrome: two cases with ectodermal features, expanding the phenotype.

Authors:  S Sharif; D Donnai
Journal:  Clin Dysmorphol       Date:  2004-10       Impact factor: 0.816

Review 2.  Rubinstein-Taybi Syndrome.

Authors:  Douglas T Hutchinson; Ryan Sullivan
Journal:  J Hand Surg Am       Date:  2015-07-01       Impact factor: 2.230

3.  Inheritance and variable expression in Rubinstein-Taybi syndrome.

Authors:  Oliver Bartsch; Wolfram Kress; Olga Kempf; Stanislav Lechno; Thomas Haaf; Ulrich Zechner
Journal:  Am J Med Genet A       Date:  2010-09       Impact factor: 2.802

4.  DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.

Authors:  Oliver Bartsch; Stefanie Schmidt; Marion Richter; Susanne Morlot; Eva Seemanová; Glenis Wiebe; Sasan Rasi
Journal:  Hum Genet       Date:  2005-07-14       Impact factor: 4.132

5.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.

Authors:  Jeroen H Roelfsema; Stefan J White; Yavuz Ariyürek; Deborah Bartholdi; Dunja Niedrist; Francesco Papadia; Carlos A Bacino; Johan T den Dunnen; Gert-Jan B van Ommen; Martijn H Breuning; Raoul C Hennekam; Dorien J M Peters
Journal:  Am J Hum Genet       Date:  2005-02-10       Impact factor: 11.025

6.  CREBBP mutations in relapsed acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Jinghui Zhang; Lawryn H Kasper; Stephanie Lerach; Debbie Payne-Turner; Letha A Phillips; Sue L Heatley; Linda Holmfeldt; J Racquel Collins-Underwood; Jing Ma; Kenneth H Buetow; Ching-Hon Pui; Sharyn D Baker; Paul K Brindle; James R Downing
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

7.  Somatic and germ-line mosaicism in Rubinstein-Taybi syndrome.

Authors:  Pei-Wen Chiang; Ni-Chung Lee; Nancy Chien; Wuh-Liang Hwu; Elaine Spector; Anne Chun-Hui Tsai
Journal:  Am J Med Genet A       Date:  2009-07       Impact factor: 2.802

8.  High frequency of mosaic CREBBP deletions in Rubinstein-Taybi syndrome patients and mapping of somatic and germ-line breakpoints.

Authors:  Cristina Gervasini; Paola Castronovo; Angela Bentivegna; Federica Mottadelli; Francesca Faravelli; Maria Luisa Giovannucci-Uzielli; Alice Pessagno; Emanuela Lucci-Cordisco; Anna Maria Pinto; Leonardo Salviati; Angelo Selicorni; Romano Tenconi; Giovanni Neri; Lidia Larizza
Journal:  Genomics       Date:  2007-09-12       Impact factor: 5.736

9.  Genotype-phenotype correlations in Rubinstein-Taybi syndrome.

Authors:  E K Schorry; M Keddache; N Lanphear; J H Rubinstein; S Srodulski; D Fletcher; R I Blough-Pfau; G A Grabowski
Journal:  Am J Med Genet A       Date:  2008-10-01       Impact factor: 2.802

10.  Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene.

Authors:  G Negri; D Milani; P Colapietro; F Forzano; M Della Monica; D Rusconi; L Consonni; L G Caffi; P Finelli; G Scarano; C Magnani; A Selicorni; S Spena; L Larizza; C Gervasini
Journal:  Clin Genet       Date:  2014-02-17       Impact factor: 4.438

View more
  3 in total

Review 1.  Lysine Acetylation and Deacetylation in Brain Development and Neuropathies.

Authors:  Alicia Tapias; Zhao-Qi Wang
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-02-02       Impact factor: 7.691

Review 2.  Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.

Authors:  Julien Van Gils; Frederique Magdinier; Patricia Fergelot; Didier Lacombe
Journal:  Genes (Basel)       Date:  2021-06-24       Impact factor: 4.096

3.  Clinical relevance of postzygotic mosaicism in Cornelia de Lange syndrome and purifying selection of NIPBL variants in blood.

Authors:  Ana Latorre-Pellicer; Marta Gil-Salvador; Ilaria Parenti; Cristina Lucia-Campos; Laura Trujillano; Iñigo Marcos-Alcalde; María Arnedo; Ángela Ascaso; Ariadna Ayerza-Casas; Rebeca Antoñanzas-Pérez; Cristina Gervasini; Maria Piccione; Milena Mariani; Axel Weber; Deniz Kanber; Alma Kuechler; Martin Munteanu; Katharina Khuller; Gloria Bueno-Lozano; Beatriz Puisac; Paulino Gómez-Puertas; Angelo Selicorni; Frank J Kaiser; Feliciano J Ramos; Juan Pié
Journal:  Sci Rep       Date:  2021-07-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.